NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trial - update solid tumors

(NCI-MATCH) Trial 

 ...The trial opened for enrollment in August 2015 with 10 treatment arms, paused for an interim analysis in November 2015, and reopened in May 2016 with a total of 24 treatment arms. Each arm expects to enroll a maximum of 35 patients.
Adults 18 years of age and older with advanced solid tumors and lymphomas that are no longer responding (or never responded) to standard therapy and have begun to grow may be candidates to take part in the NCI-MATCH trial.
The trial will examine tumor biopsy specimens from as many as 5,000 patients. The specimens undergo DNA sequencing to identify those that have genetic abnormalities that may respond to the targeted drugs selected for the trial. The drugs included in the trial have either been approved by the U.S. Food and Drug Administration (FDA) for another cancer indication or are still being tested in other clinical trials but have shown some effectiveness against tumors with a particular genetic alteration(s). Treatment arms may continue to be added to the trial over time as drug companies and others develop promising targeted therapies....